SpIntellx Inc. presented a poster at the American Association of Cancer Research (AACR) Annual Meeting on April 1, 2019, that demonstrates predictions of the risk of relapse in a pilot study of colon cancer over five years. SpIntellx is a computational and systems pathology company applying its proprietary explainable artificial intelligence (xAI) technologies to develop computational tools based on spatial analytics and systems biology for both transmitted light (HistoMaprTM) and fluorescence imaging pathology (TumorMaprTM) applications. The company is developing the TumorMapr platform to enable tailored therapeutic strategies optimizing individual outcomes by probing the spatial modulation of cancer biology in the tumor microenvironment (TME).
Colorectal cancer is the third most common cancer in men and the second in women across all regions of the world, with approximately 1.3 million newly diagnosed cases every year, the company states. While the five-year survival rates largely correlate with disease stages, adjuvant therapy decisions and treatment response predictions for at least one-third of new cases of colon cancer comprising mainly of stage II and III patients remains controversial.
A patient cohort of N = 432, distributed over stages I, II and III from hyperplexed (55 fluorescence biomarkers) formalin-fixed and paraffin-embedded (FFPE) tissue samples (AUC= 0.885 ± 0.03) was used in this pilot study.